ECOG E7208 A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Objective

This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.

https://www.clinicaltrials.gov/ct2/show/NCT01079780

Location:

Essentia Health Brainerd, Essentia Health Duluth, Essentia Health Fargo

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 07/09/12

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Gastrointestinal Cancer
Contact
Cancer Clinical Trials at 218-786-3308